• Prof Richard Beasley

    Speaker CNZM, DSC(OTAGO), DM(SOUTHAMPTON), MBCHB, FRCP(LONDON), FRACP, FAAAAI, FFOM(HON), FAPSR(NEW ZEALAND), FERS, FRSNZ

  • Prof Richard Beasley is a physician at Wellington Regional Hospital, Director of the Medical Research Institute of New Zealand, and Professor of Medicine at Victoria University of Wellington. He is an Adjunct Professor at the University of Otago and Visiting Professor, University of Southampton, United Kingdom. He is the Chair of the Asthma and Respiratory Foundation NZ Adolescent and Adult Guidelines Working Group, and a member of the ARFNZ Scientific Advisory Board, and was previously the deputy chair of the health research council of NZ. His research interests in respiratory medicine are primarily in the fields of epidemiology and clinical management. He has over 600 publications, and a Scopus H-index of 77

Event Info

Topic:

Asthma and Respiratory Foundation NZ, New 2020 Adolescent and Adult Asthma Guidelines

  • Date: 30/06/2020Time: 06:30 PM (New Zealand Standard Time: UTC+12)
BEFORE PRESCRIBING PLEASE CLICK HERE TO REVIEW FULL SYMBICORT DATA SHEET OR AVAILABLE ON REQUEST FROM ASTRAZENECA ON (09) 306 5650 OR medinfo.nz@astrazeneca.com
By continuing to use this website, you consent to the terms of Webstream Communication's Privacy Policy
This webcast has been initiated, organised and funded by AstraZeneca. The company seeks no commitment from external stakeholders to take any action as a result of the invitation or related support. The content is intended for HealthCare Professionals for medical educational purposes only. AstraZeneca is not responsible for, and may not necessarily agree with the views and opinions expressed by the participating physicians, and does not recommend any treatment or course of action. Please note the date and time of the webcast recording and seek local governmental advice for latest advice on diagnosis and treatment.

PRIVACY STATEMENT: Your personal information (“Information”) will be collected and used by AstraZeneca Pty Ltd (“AstraZeneca”) for the purpose of administration of the webcast , for follow-up purposes and for any other purpose described in AstraZeneca’s Privacy Policy (see below for link). AstraZeneca may disclose your Information to third parties such as our related entities or service providers (including IT support/service providers), some of which may be located overseas including in the US, European Union and Asia Pacific. Please refer to our Privacy Policy at for more information about how your Information is handled and how you may seek to access or correct your Information, or submit a privacy complaint. AstraZeneca’s address is 66 Talavera Road, Macquarie Park, NSW, 2113. Registered user AstraZeneca Pty. Ltd. ABN 54 009 682 311. 66 Talavera Road, Macquarie Park, NSW 2113. www.astrazeneca.com.au. For Medical Information enquiries: 3.00 805 342 or medinfo.australia@astrazeneca.com. To report an adverse event: 3.00 805 342 or via , https://aereporting.astrazeneca.com .

PBS Information: FASENRA® and FASENRA PEN™ are listed on the PBS as a Section 100 item. Refer to PBS Schedule for full authority information.

BEFORE PRESCRIBING PLEASE REVIEW FULL PRODUCT INFORMATION AVAILABLE ON REQUEST FROM ASTRAZENECA ON 1800 805 342 OR www.astrazeneca.com.au/PI

This medicinal product is subject to additional monitoring in Australia. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse events at www.tga.gov.au/reporting-problems